Home

Mark Neumann

CIK 1756211 · Chief Commercial Officer · last filed 2026-02-05

Mark Neumann is a Chief Commercial Officer who has filed 41 SEC Form 4 insider transactions across 2 companies since 2018. The most recent filing, for MANE, was dated Feb 5, 2026. Across all open-market trades the lifetime net is −$20.6M, making them a net seller over the disclosed history.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

2

Total Filings

41

Lifetime Open-Market Net

-$20.59M

Filer Profile

Reported Address
C/O INTRA-CELLULAR THERAPIES, INC.
135 ROUTE 202/206
BEDMINSTER, NJ 07921
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
MANE Chief Commercial Officer — $98.51 — $0 1 2026-02-05
Intra-Cellular Therapies, Inc. (ITCI) Delisted EVP, Chief Commercial Officer 0 $131.87 $0 -$20.59M 33 2025-04-02

Recent Filings

41 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-02-05 MANE Grant (A) — $0 EDGAR
2025-04-02 Intra-Cellular Therapies, Inc. (ITCI) Delisted Mixed −52,811 -$6.97M EDGAR
2025-03-10 Intra-Cellular Therapies, Inc. (ITCI) Delisted Mixed +11,790 -$1.14M EDGAR
2025-03-04 Intra-Cellular Therapies, Inc. (ITCI) Delisted Mixed +5,033 -$475.5K EDGAR
2025-02-04 Intra-Cellular Therapies, Inc. (ITCI) Delisted Mixed +6,288 -$600.6K EDGAR
2024-08-20 Intra-Cellular Therapies, Inc. (ITCI) Delisted Mixed — -$714.7K EDGAR
2024-08-16 — Notice (144) −18,714 -$1.40M EDGAR
2024-03-11 — Notice (144) −7,345 -$481.5K EDGAR
2024-03-11 Intra-Cellular Therapies, Inc. (ITCI) Delisted Mixed −13,132 -$1.36M EDGAR
2024-03-08 Intra-Cellular Therapies, Inc. (ITCI) Delisted Exer (M) +13,132 $0 EDGAR
Showing 1–10 of 41
Page 1 of 5
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.